Contract Development & Manufacturing (CDMO)

Contract Development & Manufacturing (CDMO)
Product Description

Our capabilities include:

  • Development Services: Process, Analytical and Formulation Development, and Non-GMP Lab-Scale Manufacturing
  • Drug Substance: Upstream Manufacturing and Downstream Processing
  • Drug Product: Clinical and Commercial Manufacturing, Drug Product cGMP Lyophilization, Packaging and Product Testing

Emergent BioSolutions Inc.

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

Emergent BioSolutions Inc.

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

Emergent BioSolutions Inc. resources (4)

  • News Emergent to manufacture Humanigen COVID-19 therapeutic

    The CDMO gears up for rapid deployment of its clinical-to-commercial manufacturing operations for its seventh collaboration to help deliver COVID-19 treatments
  • Video Women in Leadership Forum

    This year the Women in Leadership Forum will discuss why empathy is the key leadership skill required to future-proof our workplaces and create an environment where everybody can fulfil their full potential. Hear from senior leaders across the pharma supply chain as they share a defining moment from their own leadership journey that demonstrates the importance of being an empathic leader. Connect with like-minded professionals as we take a close look at our own biases and how they unconsciously affect our day-to-day perspective of others during a speed networking session that follows the storytelling session. This presentation aired as part of the CPHI Festival of Pharma
  • News Empathy is the key to successful leadership: Women in Leadership Forum

    Female life sciences leaders share their experiences and discuss the skills and attributes needed these days to become a successful leader and empower teams
  • News Emergent BioSolutions signs 5-year manufacturing agreement for J&J’s lead COVID-19 vaccine candidate

    The CDMO produce drug substance at large scale for commercial manufacturing with the first 2 years valued at approximately $480 million.